id: NEW:rare_disease_screening_infrastructure_to_NEW:early_ctx_diagnosis_rate
name: Rare Disease Screening Infrastructure â†’ Early CTX Diagnosis Rate
from_node:
  node_id: NEW:rare_disease_screening_infrastructure
  node_name: Rare Disease Screening Infrastructure
to_node:
  node_id: NEW:early_ctx_diagnosis_rate
  node_name: Early CTX Diagnosis Rate
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Investment in broader screening programs increases detection of CYP27A1 mutations'
- 'Step 2: Earlier identification of CTX patients before symptom onset or progression'
- 'Step 3: Timely initiation of chenodiol therapy while disease is still modifiable'
- 'Step 4: Prevention of cholestanol accumulation and subsequent tissue damage'
- 'Step 5: Improved long-term neurological and clinical outcomes'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Laiba Jalal et al. 2025. "FDA Approves First Targeted Treatment for Cerebrotendinous
    Xanthomatosis: A Perspective on a Landmark in Rare Lipid Storage Disease Therapy.." https://doi.org/10.1002/hsr2.71549'
  supporting_citations:
  - RESTORE Phase 3 trial (referenced in abstract - specific citation requires full-text access)
  - Additional citations require full-text access
  - Additional citations require full-text access
  doi: 10.1002/hsr2.71549
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Broader screening infrastructure for rare lipid storage diseases enables earlier diagnosis
  of CTX, allowing treatment initiation before irreversible neurological damage occurs, which the paper
  identifies as critical for achieving lasting clinical benefit.
spatial_variation:
  varies_by_geography: true
  variation_notes: Screening infrastructure varies significantly by region, healthcare system resources,
    and rare disease program development
moderators:
- name: healthcare_system_resources
  direction: strengthens
  strength: moderate
  description: Well-resourced healthcare systems can implement comprehensive rare disease screening programs
structural_competency:
  equity_implications: This mechanism emphasizes that clinical outcomes for rare diseases are structurally
    determined by screening infrastructure availability. The paper explicitly calls for 'broader screening'
    as key to improving outcomes, recognizing that individual patient outcomes depend on system-level
    investments. Geographic and socioeconomic disparities in rare disease screening capacity create inequitable
    access to early diagnosis, disadvantaging patients in under-resourced areas or healthcare systems
    without specialized genetic testing capabilities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.159955'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
